Catalyst Pharmaceutical Partners Inc.
355 Alhambra Circle
Suite 1500
Coral Gables,
FL 33134
United States - Map
Phone: 305-529-2522
Website: http://www.catalystpharma.com
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The companys principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida. Key Statistics
| |
| | Pay | Exercised | Mr. Patrick J. McEnany ,
66
Co-Founder, Chairman, Chief Exec. Officer and Pres | 394.00K | 0.00 | Dr. Hubert E. Huckel M.D.,
81
Co-Founder, Director, Member of Audit Committee, Member of Nominating & Corp. Governance Committee and Member of Compensation Committee | 27.00K | N/A | Ms. Alicia Grande CPA, CMA,
42
Chief Financial Officer, Chief Accounting Officer, VP and Treasurer | 212.00K | 0.00 | Dr. Steven R. Miller Ph.D.,
51
Chief Operating Officer and Chief Scientific Officer | 290.00K | 0.00 | Dr. Charles W. Gorodetzky M.D., Ph.D.,
75
Chief Medical Officer and Consultant | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.04(4.84%) 4:00PM EDT